(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -18.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Arrowhead Pharmaceuticals's revenue in 2025 is $829,448,000.On average, 16 Wall Street analysts forecast ARWR's revenue for 2026 to be $57,265,458,226, with the lowest ARWR revenue forecast at $13,535,595,408, and the highest ARWR revenue forecast at $92,233,703,220. On average, 12 Wall Street analysts forecast ARWR's revenue for 2027 to be $47,807,680,607, with the lowest ARWR revenue forecast at $18,460,593,219, and the highest ARWR revenue forecast at $71,200,876,973.
In 2028, ARWR is forecast to generate $68,678,893,481 in revenue, with the lowest revenue forecast at $33,938,808,544 and the highest revenue forecast at $120,354,430,300.